Your genetics can affect how much weight you lose on Ozempic, Wegovy, Mounjaro, and Zepbound, and how likely you are to feel nauseous. Gene2Rx reads the genes behind your GLP-1 response and gives you a personalized report in minutes.
Why do GLP-1s work so well for some people and not others?
Across 27,885 people tracked on GLP-1s, the typical loss was around 12 percent of body weight. The spread around that average is enormous: in a large semaglutide trial, about a third of patients lost less than 5 percent or gained weight, while roughly one in twenty lost more than a quarter of their body weight. Part of that spread is written in your DNA.
0 to 25%+
Range of weight loss seen between individuals on the same GLP-1
#1
Nausea and GI side effects are the most common reason people stop GLP-1s
2 genes
GLP1R and GIPR are the two genes most tied to how you respond
Dose, diet, activity, and other medications all matter. Genetics is one lever you cannot change but can plan around. Knowing your GLP1R and GIPR results up front helps set realistic expectations and can inform how quickly you move up in dose.
Your genetics, your GLP-1 response
Based on recent GLP-1 pharmacogenetics research, including a 2026 study of GLP1R and GIPR variants published in Nature. Two common variants change how strongly your body responds to these drugs.
Study size
27,885
people on GLP-1s studied
Journal
Nature
peer reviewed, April 2026
Research group
23andMe
Research Institute study
Genes
2 genes
read from your own DNA file
Su QJ, et al. Genetic predictors of GLP1 receptor agonist weight loss and side effects. Nature 653:770-775 (2026). The effect was measured most precisely in people of European ancestry, where the variant is most common.
The same variant, two different drugs
Odds of moderate-to-severe vomiting for carriers of the GIPR Gln354 variant, compared with non-carriers on the same drug.
Odds of vomiting vs non-carriers, with 95% confidence interval
Tirzepatide is sold as Mounjaro and Zepbound; semaglutide as Ozempic and Wegovy. This is the most directly useful GLP-1 result we report: if tirzepatide nausea is a problem for you, this variant does not affect semaglutide. Bars show the 95% confidence interval, and semaglutide's crosses "no change", which is why we report it as no measurable effect rather than as a benefit.
View as a table
Drug
Odds vs non-carriers
95% CI
Significance
Tirzepatide
1.85×
1.54 to 2.24
P = 1.1 × 10-10
Semaglutide
0.93×
0.85 to 1.04
Not significant (P = 0.23)
Derived from the reported effect-allele odds ratios in Su QJ et al., Nature 653:770-775 (2026), Figure 2c, expressed here for the Gln354 risk allele.
GLP1R encodes the GLP-1 receptor, the direct target of every GLP-1 drug. A common signal-peptide variant changes how efficiently the receptor reaches the cell surface, and with it the strength of the response. It matters for all GLP-1s, including semaglutide and tirzepatide.
Impacts
Weight loss on GLP-1s
Effect
~0.76 kg more weight loss per copy of the Leu7 allele
Frequency
Leu7 allele carried by about 40% of people of European ancestry, 28% Admixed American, 16% East Asian, 7% African
GIPR encodes the GIP receptor. It only matters for drugs that hit the GIP receptor, which means tirzepatide (Mounjaro, Zepbound) but not semaglutide. This is the most directly actionable GLP-1 genetic result we report.
Impacts
Nausea and vomiting risk on tirzepatide
Effect
~1.8x higher odds of moderate-to-severe vomiting for Gln354 carriers; nausea is also raised
Specific to
Tirzepatide only; does not apply to semaglutide
Combined
Carrying two copies of the risk allele at both GLP1R and GIPR raises the odds of tirzepatide vomiting 14.8-fold
Actionable
If tirzepatide nausea is intolerable, semaglutide is unaffected by this variant
These are research-backed signals, not formal CPIC or FDA guidelines. There is no contraindication here. Most people do well on GLP-1s. Your results help set expectations and inform how you and your clinician approach titration.
What is in your GLP-1 report
Clear, personalized results you can read in minutes and share with your clinician. Included with the Complete report.
Expected weight loss
How your GLP1R genetics may influence how much weight you lose on GLP-1s.
Nausea and side-effect risk
Your GLP1R and GIPR variants and what they mean for GI side effects, including tirzepatide-specific risk.
Medication guidance
Pharmacogenetic insights for 120 medications, including GLP-1s, so you see the full picture.
Actionable insights
Plain-language results you can bring to a conversation with your healthcare provider.
Get your GLP-1 genetics without a prescription or an appointment.
Results in minutes
No lab wait. Your report is ready almost as soon as you upload.
Affordable
A fraction of the cost of clinical pharmacogenetic panels.
Already have 23andMe, AncestryDNA, MyHeritage, or WGS data?
Turn the genetic data you already have into GLP-1 and medication insights today.
23andMe
AncestryDNA
MyHeritage
TellMeGen
Nebula Genomics (WGS)
Consumer genotyping arrays and whole genome sequencing VCFs are both supported. GRCh37 and GRCh38 both work. A whole genome sequencing VCF adds $20 per report for whole genome processing.
Get your GLP-1 report
Your GLP1R and GIPR results come in the Complete report, alongside every other medication we cover. Upload the DNA data you already have and read it in minutes.
Complete report
One-time payment
$50No subscription, no prescription.
Your GLP-1 results: GLP1R and GIPR, covering semaglutide, tirzepatide, and retatrutide
Weight-loss response and nausea risk, explained in plain language
120 medications across all 34 drug classes, included
Ready in under a minute, yours to keep and share with your clinician
Always consult your healthcare provider before making any changes to your medications or dosages.
Direct-to-consumer genetic data is not clinical grade. GLP-1 pharmacogenetic findings are research-backed signals, not formal CPIC or FDA guidelines. The information in our reports should be used only as a conversation starter with your healthcare provider to discuss appropriate clinical laboratory testing.
This report does not diagnose any condition and does not determine whether a GLP-1 medication is right for you. That is a decision for you and your clinician.
GLP-1 genetics questions
What people ask before checking their GLP-1 genetics with Gene2Rx
Which GLP-1 medications does the report cover?
Semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound), and the investigational triple agonist retatrutide. The report reads the genes that influence GLP-1 response, GLP1R and GIPR, as part of 120 medications.
Will this tell me whether Ozempic will work for me?
It cannot guarantee an outcome. Genetics is one factor among many, alongside dose, diet, activity, and other medications. Your GLP1R result helps set expectations for how much weight loss and how much nausea to anticipate, and can inform how quickly you titrate up. Treat it as a conversation starter with your clinician, not a clinical diagnosis.
Should I change my medication or dose based on this report?
No. Direct-to-consumer genetic data is not clinical grade. Do not start, stop, or change a medication or a dose without talking to your healthcare provider first. Use the report to have a more informed conversation.
What genetic data do I need?
A raw DNA file from 23andMe, AncestryDNA, MyHeritage, or TellMeGen, or a whole genome sequencing VCF from any provider such as Nebula Genomics, Dante Labs, or Sequencing.com. GRCh37 and GRCh38 are both supported. If you are not sure your file will work, email support@gene2rx.com and we will take a look.
How is this different from a test my clinic would run?
A clinical laboratory test is validated for medical decision making. Gene2Rx analyzes consumer genetic data, which is not clinical grade, and surfaces research-backed signals in minutes for a fraction of the cost. It is meant to inform a discussion with your clinician, who can order clinical testing if it is warranted.
See how your genetics shape your GLP-1 response
Upload the DNA data you already have and get your personalized GLP-1 report in minutes.
